Login to Your Account

Other News To Note

Thursday, June 14, 2012

• BioAlliance Pharma SA, of Paris, inked an exclusive license agreement for Sitavig (acyclovir Lauriad) with Abic Marketing Ltd., a subsidiary of Jerusalem-based Teva Pharmaceutical Industries Ltd. for commercialization rights in Israel. Sitavig, based on BioAlliance's mucoadhesive buccal technology, is in development for treating recurrent labial herpes in immunocompetent patients presenting more than four episodes per year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription